Aurinia Pharmaceuticals Inc (AUPH)

[Whalatane]

Z. They have probably made the calculation that since they have so much cash on hand , they can afford a slow grind towards break even .....with their current strategy.
If they could interest a buyer ( which I doubt for reasons I've listed before ) one of their selling pts would be that the buyer could ramp up scripts by lowering the price of Lupy ...especially if the buyer is a BP with an existing Kidney disease sales force ( so less marketing expense ) .

Main challenge facing those that want to prescribe Lupy is the insurers mandating patients fail on all alternative treatments first ...including Benlysta

Kiwi